| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 04.04.2017 og
angivet som gældende fra 04.04.2017 (2831
dage). |
Ingen historik.
| Branche | | Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900). |
| Sidst opdateret den 08.05.2023 og
angivet som gældende fra 01.01.2023 (733
dage). |
| Historik | Start | Stop |
|---|
| Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900) | 01.01.2023 | |
| Fremstilling af farmaceutiske præparater (212000) | 04.04.2017 | 31.12.2022 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 04.04.2017 og
angivet som gældende fra 04.04.2017 (2831
dage). |
Ingen historik.
| Kontaktoplysninger | | dannemann@draupnir.bio. |
| Sidst opdateret den 04.06.2024 og
angivet som gældende fra 04.06.2024 (213
dage). |
Ingen historik.
| Telefonnummer | | 51500560. |
| Sidst opdateret den 04.06.2024 og
angivet som gældende fra 04.06.2024 (213
dage). |
Ingen historik.
| Navne | | Draupnir Bio ApS. |
| Sidst opdateret den 04.04.2017 og
angivet som gældende fra 04.04.2017 (2831
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse. |
| Sidst opdateret den 28.10.2019 og
angivet som gældende fra 28.10.2019 (1894
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | formanden + 1 bestyrelsesmedlem |
| formanden + 1 direktør |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse | 28.10.2019 | |
| Selskabet tegnes af Emmanuelle Coutanceau, Peter Hans Andreas Seeberger og et bestyrelsesmedlem i forening, af Emmanuelle Coutanceau i forening med en direktør eller af den samlede bestyrelse | 05.11.2018 | 27.10.2019 |
| Selskabet tegnes af to bestyrelsesmedlemmer i forening, af et bestyrelsesmedlem i forening med en direktør eller af den samlede bestyrelse | 04.04.2017 | 04.11.2018 |
Type af revisorbistand:Auditor's report on audited financial statements
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State-Authorised Public Accountant
Virksomhedens regnskabsklasse:Reporting class B
Grundlag for konklusion (revision):Basis for Opinion We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):Opinion We have audited the financial statements of Draupnir Bio ApS for the financial year 01. 01. 2023 - 31. 12. 2023, which comprise the income statement, statement of comprehensive income, balance sheet, statement of changes in equity, cash flow statement and notes, including material accounting policy information. The financial statements are prepared in accordance with IFRS Accounting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31. 12. 2023 and of the results of its operations and cash flows for the financial year 01. 01. 2023 - 31. 12. 2023 in accordance with IFRS Accounting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on management’s commentary Management is responsible for the management commentary. Our opinion on the financial statements døs not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required by relevant laws and regulations. Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the information required by relevant laws and regulations. We did not identify any material misstatement of the management commentary. 0
| Historik | Start | Stop |
|---|
| Forskning og eksperimentel udvikling indenfor bioteknologi | 04.04.2017 | 31.12.2022 |
| Virksomheden har ikke ændret Bibranche
i
sin
levetid. |
Ingen nuværende registrering.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | www.draupnir.bio. |
| Sidst opdateret den 04.06.2024 og
angivet som gældende fra 04.06.2024 (213
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration